We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Context Therapeutics Inc (CNTX) USD0.001

Sell:$2.00 Buy:$2.13 Change: $0.15 (6.85%)
Market closed |  Prices as at close on 17 July 2024 | Switch to live prices |
Sell:$2.00
Buy:$2.13
Change: $0.15 (6.85%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 17 July 2024 | Switch to live prices |
Sell:$2.00
Buy:$2.13
Change: $0.15 (6.85%)
Market closed |  Prices as at close on 17 July 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Context Therapeutics Inc. is a biopharmaceutical company advancing medicines for solid tumors. The Company is building an advanced portfolio of clinical-stage T cell engaging bispecific therapeutics, including CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody, and CT-95, a potential first-in-class mesothelin x CD3 bispecific antibody. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors, including ovarian, endometrial, testicular, and lung, and absent from or expressed at low levels in healthy adult tissues. CTIM-76 is capable of binding to tumor cells expressing CLDN6 and stimulating intra-tumoral T cells by the CD3 arm that is designed to be activated only upon tumor engagement while silent elsewhere. CTIM-76 has the potential for a wide therapeutic window. The Company’s CT-95 is being developed as a therapy for advanced cancers associated with mesothelin (MSLN) expression.

Contact details

Address:
2001 Market Street, Suite 3915 Unit #15
PHILADELPHIA
19103
United States
Telephone:
+1 (267) 2257416
Website:
https://www.contexttherapeutics.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CNTX
ISIN:
US21077P1084
Market cap:
$165.00 million
Shares in issue:
75.00 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Martin Lehr
    President, Chief Executive Officer, Director
  • Jennifer Minai-Azary
    Chief Financial Officer, Treasurer
  • Christopher Beck
    Senior Vice President - Operations
  • Priya Marreddy
    Vice President - Clinical Operations
  • Tarek Sahmoud
    Chief Medical Officer
  • Alex Levit
    Chief Legal Officer and Corporate Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.